Faculty

Faculty

Principal Investigator

The Center is home to China’s top structural biology research teams, featuring CAS academicians, and winners of the National Science Fund for Distinguished Young Scholars.

Feng Qian

Principal Investigator

(1) Drug design and delivery against pancreatic cancer Pancreatic cancer is known as the "king of cancers" and there is still a serious lack of effective therapeutic agents. The unique physiology, tumor biology, and tumor immune microenvironment of pancreatic cancer contribute to this dilemma. We are committed to understanding and exploiting the mechanisms of albumin transport and metabolism in pancreatic cancer, in order to design new drugs and drug delivery strategies for pancreatic cancer treatment. At the same time, we also explore the possibility of using some natural products with unique pharmacological mechanisms for pancreatic cancer therapy. (2) Drug design and delivery for retinal diseases As the population continues to age, blinding retinal diseases such as age-related macular degeneration, diabetic macular edema, and glaucoma continue to climb. The most effective mode of drug delivery for these fundus diseases is intravitreal injection. However, the molecular design and delivery of drugs greatly affects the pharmacological activity, potency, injectability, long-term stability, and other key characteristics of such drugs, thereby greatly affecting efficacy, compliance, and ultimately control of disease progression. We strive to understand the relationship between structure and function of drug targets, explore the influence of protein drug structure on their solution and pharmacokinetic properties, based on which we are engineering novel protein drugs for the efficient treatment of multiple fundus diseases. (3) Physical pharmaceutics and biopharmaceutics of various types of drugs As new drug types continue to evolve and iterate, we continue to study drug-drug, drug-excipient, and formulation-bio-tissue interactions for various classes of drugs, such as poorly soluble and difficult-to-absorb (BCS 2/3/4 “beyond-rule-of-five” drugs, including various small molecules, peptides, etc.), antibodies, and fusion proteins. Furthermore, we investiga